Prof. Dr. Nuri KARADURMUŞ | AVESİS

Akademik Veri Yönetim Sistemi

Yayınlar & Eserler

Makaleler 188

1. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Bolek H., Sertesen Camoz E., Kuzu O. F., Karakas H., Sim S., Sekmek S., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

Creative Commons License

2. Prognostic value of cachexia index in HR +/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors

Keskin G. S. Y., Turgut G. G., Yildirim G., Tuzun E. K., Aslan V., AYKAN M. B., et al.

BMC Cancer , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

3. Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

ŞAHİN T. K., Orhan C., Ozercan I. H., Muglu H., Er B., Akyildiz A., et al.

Experimental Hematology and Oncology , cilt.15, sa.1, 2026 (SCI-Expanded, Scopus)

4. Clinical characteristics and survival outcomes of adult inflammatory myofibroblastic tumor: a retrospective single-center study

Dumludağ A., Yıldırım G., Topal A., Tüzün E. K., Karadurmuş B., ERTÜRK İ., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

5. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

Brufsky A., Park Y. H., Bidard F., Mayer E. L., Janni W., Ma C., et al.

Oncologist , cilt.31, sa.9, 2026 (SCI-Expanded, Scopus)

6. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

Turner N. C., Mayer E. L., Park Y. H., Janni W., Ma C., Cristofanilli M., et al.

The Lancet Oncology , cilt.27, sa.8, ss.941-958, 2026 (SCI-Expanded, Scopus)

7. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

Günaltılı M., Bölek H., Kaplan Tüzün E., Usta S., Efil S. C., AKKUŞ A. F., et al.

Cancers , cilt.18, sa.13, 2026 (SCI-Expanded, Scopus)

8. Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study

Karabuga B., Büyükkör M., Karaçin C., Konca Karabuga E., Yildiz S., Gül Güneysu G., et al.

In Vivo , cilt.40, sa.4, ss.2476-2488, 2026 (SCI-Expanded, Scopus)

9. Antibody–drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure

Kemik F., ŞAHİN T. K., ÖZÇELİK H., Sezer A., BAŞARAN G., Açıkel Yüksel S., et al.

Breast , cilt.87, 2026 (SCI-Expanded, Scopus)

10. Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort—A Turkish Oncology Group (TOG) Study

Kidi M. M., Asoglu H., Soysal M., KÖŞECİ T., KARA İ. O., ŞAHİN B., et al.

Medicina (Lithuania) , cilt.62, sa.6, 2026 (SCI-Expanded, Scopus)

11. Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer

Im S., Kalinsky K., Jhaveri K., Loibl S., Turner N., Saura C., et al.

ESMO Open , cilt.11, sa.6, 2026 (SCI-Expanded, Scopus)

12. Pre-Transplant Prognostic Nutritional Index Independently Predicts Progression-Free Survival After Autologous Stem Cell Transplantation in Lymphoma

Atacan H., Aslan V., Topal A., Mammadzada N., Yıldırım G., Güneysu G. G., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

13. The Royal Marsden Hospital Score Independently Predicts Overall Survival in Patients with De Novo Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors: A Multicenter Retrospective Analysis

Doğan T., Taş S., Güçlü Kantar T., Karahan İ., Gökçen Demiray A., AYKAN M. B., et al.

Journal of Clinical Medicine , cilt.15, sa.10, 2026 (SCI-Expanded, Scopus)

14. Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

Curigliano G., O'Shaughnessy J., Bidard F., Casalnuovo M., Kim S., Tokunaga E., et al.

ESMO Open , cilt.11, sa.4, 2026 (SCI-Expanded, Scopus)

15. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

Güzel H. G., KIVRAK SALİM D., Kılıçkap S., Kemal Y., Akosman C., Köseoğlu Ç., et al.

Oncologist , cilt.31, sa.4, 2026 (SCI-Expanded, Scopus)

16. Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy☆

Mayer E., Bidard F., Park Y., Janni W., Ma C., Cristofanilli M., et al.

Annals of Oncology , cilt.37, sa.2, ss.180-193, 2026 (SCI-Expanded, Scopus)

17. Assessment of Meet-URO and CANLPH Prognostic Models in Metastatic RCC: Insights from a Single-Institution Cohort Predominantly Treated with TKIs

Kuzu Ö. F., KARADURMUŞ N., Kanat N. B., Özel Bozdağ D. İ., Karadurmuş B., Kaplan Tüzün E., et al.

Diagnostics , cilt.16, sa.3, 2026 (SCI-Expanded, Scopus)

18. Associations of posttraumatic growth and social support with caregiver burden in informal caregivers of women with gynecologic cancer

Sahingoz Alpargan M., Uslu-Sahan F., KARADURMUŞ N.

Psychology, Health and Medicine , 2026 (SCI-Expanded, SSCI, Scopus)

19. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study☆

Fizazi K., Clarke N., De Santis M., Uemura H., Fay A., KARADURMUŞ N., et al.

Annals of Oncology , cilt.37, sa.1, ss.53-68, 2026 (SCI-Expanded, Scopus)

20. Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions

Cicin I., Kus T., ERALP Y., ÜRÜN Y., Demirci U., Bahsi T., et al.

European Journal of Cancer Care , cilt.2026, 2026 (SCI-Expanded, SSCI, Scopus)

21. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

Erol C., Zeynelgil E., Hizal M., Dumludag A., Erciyestepe M., Kalaci E., et al.

Clinical and Translational Oncology , 2026 (SCI-Expanded, Scopus)

22. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

ŞAHİN T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.

Therapeutic Advances in Medical Oncology , cilt.18, 2026 (SCI-Expanded, Scopus)

23. Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study

Ökten İ. N., Baydaş T., Yıldırım M. E., Bilir C., YALÇIN Ş., ÇUBUKÇU E., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

24. The temporal evaluation of RAS mutation by liquid biopsy at progression after bevacizumab-based treatment in patients with metastatic colorectal cancer

Bilgetekin I., Demirci U., Yildirim H. C., Dogan M., Karacin C., Onur İ. D., et al.

Clinical and Translational Oncology , 2026 (SCI-Expanded, Scopus)

25. Evaluation of the Cellsway Microfluidic CTC Enrichment and Identification Platform for CTC Detection in Metastatic NSCLC

Özgür E., Çırçır A., Doğan B. Ş., Şahin Ş., Karayalçın G., Demir M. A., et al.

Biosensors , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

26. The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients

Kuzu Ö. F., KARADURMUŞ N., Kanat N. B., Köseoğlu Ç., Dumludağ A., Topal A., et al.

Journal of Clinical Medicine , cilt.14, sa.24, 2025 (SCI-Expanded, Scopus)

27. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

Kuzu O. F., Bolek H., Sertesen Camoz E., Karakas H., Sekmek S., Sim S., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

28. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

ŞENDUR M. A. N., Hizal M., Çakar B., AKTEPE O. H., Eraslan E., ARIK Z., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

29. Comparison of Third-Line Treatment Options in Patients with Metastatic Renal Cell Carcinoma

Kuzu Ö. F., Kanat N. B., Bozdağ D. İ. Ö., Topal A., KARADURMUŞ N., ERTÜRK İ.

Acta Haematologica Oncologica Turcica , cilt.58, sa.3, ss.202-205, 2025 (Scopus, TRDizin)

Creative Commons License

30. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

Telli T. A., Tatlı A. M., ALAN Ö., Keskin G. Y., KARADURMUŞ N., KARAKAYA S., et al.

Clinical Lung Cancer , cilt.26, sa.8, 2025 (SCI-Expanded, Scopus)

31. Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a

Soran A., Göktepe B., Demirors B., Aytac O., Ozbas S., DOĞAN L., et al.

Current Oncology , cilt.32, sa.10, 2025 (SCI-Expanded, Scopus)

Creative Commons License

32. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Cho B. C., Li W., Spira A. I., Sauder M., Feldman J., Bozorgmehr F., et al.

Journal of Thoracic Oncology , cilt.20, sa.10, ss.1517-1530, 2025 (SCI-Expanded, Scopus)

33. The Impact of Clinical and Morphometric Parameters on Hematopoietic Engraftment Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Germ Cell Tumors

Kuzu Ö. F., KARADURMUŞ N., Acar A. G., Kanat N. B., Köseoğlu Ç., Dumludağ A., et al.

Medicina (Lithuania) , cilt.61, sa.9, 2025 (SCI-Expanded, Scopus)

34. A Real-World Evaluation of Clinical Prognostic Scores in Advanced Melanoma Treated with Immune Checkpoint Inhibitors

Yildiran Keskin G. S., KARADURMUŞ N.

Journal of Clinical Medicine , cilt.14, sa.18, 2025 (SCI-Expanded, Scopus)

35. Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study

ŞENDUR M. A. N., KARADURMUŞ N., Cicin I., Gumus M., Demirci U., Ozyilkan O., et al.

Future Oncology , cilt.21, sa.19, ss.2525-2535, 2025 (SCI-Expanded, Scopus)

36. First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer.

Bidard F., Mayer E. L., Park Y. H., Janni W., Ma C., Cristofanilli M., et al.

New England Journal of Medicine , cilt.393, sa.6, ss.569-580, 2025 (SCI-Expanded, Scopus)

37. Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients

Topal A., Akdağ G., Dumludağ A., Köseoğlu Ç., Kuzu Ö. F., Atacan H., et al.

Journal of Oncological Science , cilt.11, sa.2, ss.96-103, 2025 (Scopus, TRDizin)

Creative Commons License

38. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Bolek H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Clinical and Translational Oncology , cilt.27, sa.7, ss.3110-3120, 2025 (SCI-Expanded, Scopus)

39. The impact of smoking on nivolumab outcomes in renal cell carcinoma: Real-world data from the Turkish Oncology Group Kidney Cancer Consortium

Sertesen Camoz E., Bolek H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., et al.

Oncologist , cilt.30, sa.7, 2025 (SCI-Expanded, Scopus)

40. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.

Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus)

41. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Paz-Ares L., Borghaei H., Liu S. V., Peters S., Herbst R. S., Stencel K., et al.

The Lancet , cilt.405, sa.10495, ss.2129-2143, 2025 (SCI-Expanded, Scopus)

42. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

TURAN N., ÇİL T., Artac M., Hacibekiroglu I., Sümbül A. T., Uncu D., et al.

Journal of Clinical Oncology , cilt.43, 2025 (SCI-Expanded, Scopus)

43. Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from Turkey

Yildiran Keskin G. S., YETGİNOĞLU Ö., VURĞUN S., Guzel E. Z., Ozkan F. E., Yilmaz M., et al.

Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus)

Creative Commons License

44. Real-world experience with dose-adjusted EPOCH-R in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma: A multicenter analysis from Turkey.

Kidi M. M., BAYRAM E., Soysal M., AYKAN M. B., KARADURMUŞ N., BARIŞTA İ., et al.

Journal of Clinical Oncology , cilt.43, 2025 (SCI-Expanded, Scopus)

45. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

Bolek H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Cancer Communications , cilt.45, sa.5, ss.572-576, 2025 (SCI-Expanded, Scopus)

46. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Yildirim M. E., KARADURMUŞ N., Ökten İ. N., TÜRK H. M., Urakçı Z., Arslan Ç., et al.

Journal of Oncology Pharmacy Practice , cilt.31, sa.3, ss.404-411, 2025 (SCI-Expanded, Scopus)

47. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.

Medicina (Lithuania) , cilt.61, sa.3, 2025 (SCI-Expanded, Scopus)

48. The Power of Reiki: Its Effects on Pain and Biochemical Parameters in Patients Undergoing Bone Marrow Transplantation: A Randomized Prospective Controlled Study

Bektas Akpinar N., ÜNAL N., Alıncak G., Pörücü C., Yurtsever S., KARADURMUŞ N.

Pain Management Nursing , cilt.26, sa.1, 2025 (SCI-Expanded, SSCI, Scopus)

49. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Bölek H., Sertesen E., Kuzu O. F., Tural D., Sim S., Nahit Şendur M. A., et al.

Clinical Genitourinary Cancer , cilt.23, sa.1, 2025 (SCI-Expanded, Scopus)

50. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

AYKAN M. B., Bölek H., YEKEDÜZ E., Sertesen E., Tural D., Karaçin C., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

51. Efficacy and Safety of Three Cycles of TIP and Sequential High Dose Chemotherapy in Patients with Testicular Non-Seminomatous Germ Cell Tumors

AYKAN M. B., Yildiran Keskin G., ERTÜRK İ., Acar R., Kose A. F., KARADURMUŞ N.

Journal of Clinical Medicine , cilt.14, sa.1, 2025 (SCI-Expanded, Scopus)

Creative Commons License

52. Management of cancer-associated venous thromboembolism (CAT): Expert opinion and insights from the current guidelines

KARADURMUŞ N., Doganci S., Sendur M. A. N., Saydam O., Ozdengulsun B., Ahi Dundar E., et al.

Turkish Journal of Vascular Surgery , cilt.34, sa.2, ss.181-191, 2025 (Scopus, TRDizin)

Creative Commons License

53. The Cost-effectiveness of National Lung Cancer Screening in Türkiye

Malhan S., Göksel T., KARADURMUŞ N., Kavakli K., SAVAŞ R., Şendur M. A. N., et al.

Turk Onkoloji Dergisi , cilt.40, sa.1, ss.30-42, 2025 (ESCI, Scopus, TRDizin)

54. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Sekmek S., Bolek H., Kuzu O. F., Camoz E. S., Sim S., Karakaş H., et al.

Immunotherapy , cilt.17, sa.9, ss.649-655, 2025 (SCI-Expanded, Scopus)

55. Quality of life and psychosocial challenges in metastatic breast cancer: the need for tailored interventions in Turkiye

BAŞARAN G., KARADURMUŞ N., Bugdayci Basal F., Aroyo V., Savas E., Ozturk Saglam O. F., et al.

Future Science OA , cilt.11, sa.1, 2025 (ESCI, Scopus)

56. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., KARAKAYA S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

57. Salvage Treatment for Extragonadal Germ Cell Tumours: High-Dose Chemotherapy and Autologous Stem Cell Transplantation Outcomes—A Single-Centre Experience

Topal A., ERTÜRK İ., Koseoglu C., Dumludag A., Kuzu Ö. F., Karadurmus B., et al.

Journal of Clinical Medicine , cilt.13, sa.21, 2024 (SCI-Expanded, Scopus)

58. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Mahidin E. I. B. M., Yap Y. S., Im S., Rihani J., Chung W., Babu K. G., et al.

Journal of Clinical Oncology , cilt.42, sa.23, ss.2812-2821, 2024 (SCI-Expanded, Scopus)

59. The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience

Topal A., ERTÜRK İ., Koseoglu C., Dumludag A., Kuzu Ö. F., Durmaz P., et al.

Clinical Genitourinary Cancer , cilt.22, sa.4, 2024 (SCI-Expanded, Scopus)

60. Evaluation of Demographic and Clinical Characteristics of Turkish Patients With Primary Cutaneous Melanoma: A 5-Year Experience of a Tertiary Referral Center

Gahramanov I., AKOĞLU G., KARAİSMAİLOĞLU E., KARADURMUŞ N.

Dermatology Practical and Conceptual , cilt.14, sa.3, 2024 (SCI-Expanded, Scopus)

61. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.

Clinical Genitourinary Cancer , cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)

62. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

Yang J. C., Han B., De La Mora Jiménez E., Lee J., Koralewski P., KARADURMUŞ N., et al.

Journal of Thoracic Oncology , cilt.19, sa.6, ss.941-953, 2024 (SCI-Expanded, Scopus)

63. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., KARADURMUŞ N., KORKMAZ T., Yumuk P. F., Cicin I., et al.

Medicine (United States) , cilt.103, sa.21, 2024 (SCI-Expanded, Scopus)

64. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience

Yildiran Keskin G. S., ERTÜRK İ., AYKAN M. B., Acar R., Dumludag A., Topal A., et al.

Oncology Research and Treatment , cilt.47, sa.6, ss.262-272, 2024 (SCI-Expanded, Scopus)

65. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

GÜVEN D. C., AYKAN M. B., Muglu H., BAYRAM E., Helvaci K., Dursun B., et al.

Cancer Medicine , cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)

66. Efficacy of Perioperative FLOT Therapy in Locally Advanced Gastric Cancer and the Associated Prognostic Factors

Yildiran Keskin G. S., ERTÜRK İ., AYKAN M. B., Acar R., Topal A., Dumludağ A., et al.

Journal of Oncological Science , cilt.10, sa.2, ss.97-104, 2024 (Scopus, TRDizin) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

67. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Cicin I., KARADURMUŞ N., BİLİCİ A., Bahsi T., Sendur M. A., Demirci U., et al.

Future Oncology , cilt.20, sa.15, ss.1031-1045, 2024 (SCI-Expanded, Scopus)

68. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

KARADURMUŞ N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., et al.

Current Medical Research and Opinion , cilt.40, sa.7, ss.1171-1178, 2024 (SCI-Expanded, Scopus)

69. A Cost-of-illness Study on The Economic Burden of Breast Cancer in Türkiye: A Delphi Panel-based Analysis of Direct and Indirect Costs

Malhan S., AKINCI M. B., AKYÜREK N., Bilici A., Demirci U., Geredeli Ç., et al.

Turk Onkoloji Dergisi , cilt.39, sa.4, ss.383-392, 2024 (ESCI, Scopus, TRDizin)

70. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.

BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

71. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

Kilickap S., AK S., Dursun O. U., Sendur M. A., KARADURMUŞ N., Demirci U.

Future Oncology , cilt.19, sa.29, ss.2003-2012, 2023 (SCI-Expanded, Scopus)

72. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling

Özdemir Z., Çevik E., Öksüzoğlu Ö. B. Ç., DOĞAN M., ATEŞ Ö., Esin E., et al.

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis , cilt.827, 2023 (SCI-Expanded, Scopus)

73. Major and minor salivary gland cancers: A multicenter retrospective study

HACIOĞLU M. B., ERDOĞAN B., Bardakcı M., ALGIN E., Gulbagcı B., Hacibekiroglu I., et al.

Head and Neck , cilt.45, sa.7, ss.1643-1653, 2023 (SCI-Expanded, Scopus)

74. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.

Clinical Genitourinary Cancer , cilt.21, sa.3, ss.334-341, 2023 (SCI-Expanded, Scopus)

75. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkish oncology group study

Acar R., PAYDAŞ S., YILDIRIM M., Kiliçarslan E., ŞAHİN U., DOĞAN A. A., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.8, 2023 (SCI-Expanded, Scopus)

76. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., BAYRAM E., Demirel B. C., et al.

Future Oncology , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)

77. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

YEKEDÜZ E., KARAKAYA S., ERTÜRK İ., Tural D., Uçar G., Şentürk Öztaş N., et al.

Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)

78. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., YEKEDÜZ E., GÜVEN D. C., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.72-78, 2023 (Scopus, TRDizin)

79. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

BİLİCİ A., Olmez O. F., Kaplan M. A., Oksuzoglu B., Sezer A., KARADURMUŞ N., et al.

Acta Oncologica , cilt.62, sa.4, ss.381-390, 2023 (SCI-Expanded, Scopus)

80. Immunotherapy for Lung Cancer

KARADURMUŞ N., AKYÜREK N., Aydiner A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.97-111, 2023 (Scopus, TRDizin)

81. Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations

Kahraman S., Bardakci M., AYKAN M. B., Yasar S., Erol C., Hizal M., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.2, ss.347-354, 2023 (SCI-Expanded, Scopus)

82. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Gürbüz M., Kiliçkap S., BİLİCİ A., KARADURMUŞ N., Sezer A., ŞENDUR M. A. N., et al.

Medicine (United States) , cilt.101, sa.50, 2022 (SCI-Expanded, Scopus)

83. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded, Scopus)

84. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

YEKEDÜZ E., Tural D., ERTÜRK İ., KARAKAYA S., Erol C., Ercelep Ö., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded, Scopus)

Creative Commons License

85. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Yücel K. B., YEKEDÜZ E., KARAKAYA S., Tural D., ERTÜRK İ., Erol C., et al.

Scientific Reports , cilt.12, sa.1, 2022 (SCI-Expanded, Scopus)

Creative Commons License

86. Efficacy of ifosfamide, carboplatin and etoposide chemotherapy protocol in relapsed refractory germ cell tumors

AYKAN M. B., ERTÜRK İ., Acar R., Keskin G. S., Örnek E., KARADURMUŞ N.

Gulhane Medical Journal , cilt.64, sa.3, ss.229-234, 2022 (Scopus, TRDizin)

87. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

ÖZDEMİR Ö., Zengel B., Yildiz Y., Uluç B. O., ÇABUK D., Ozden E., et al.

Anti-Cancer Drugs , cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded, Scopus)

88. Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours

AYKAN M. B., Yildiran G. S., Akcan E., Acar R., ERTÜRK İ., KARADURMUŞ N.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.7, ss.880-884, 2022 (SCI-Expanded, Scopus)

Creative Commons License

89. Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G., Şahin S., et al.

Journal of Gastrointestinal Cancer , cilt.53, sa.2, ss.282-288, 2022 (ESCI, Scopus)

90. The assessment of rheumatologic immune-related adverse events with immune checkpoint inhibitors

TEKGÖZ E., Colak S., Acar R., ERTÜRK İ., AYKAN M. B., Yıldız B., et al.

Gulhane Medical Journal , cilt.64, sa.1, ss.103-109, 2022 (Scopus, TRDizin)

91. Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome

YAZICI O., Ucar G., SÜTCÜOĞLU O., Turhal N. S., Yildiz B., Karamouzis M., et al.

Current Medical Research and Opinion , cilt.38, sa.4, ss.579-586, 2022 (SCI-Expanded, Scopus)

92. Retrospective Analysis of Testicular Germ Cell Tumor Patients with Brain Metastases: A Single-Center Experience

AYKAN M. B., Yildiran G. S., Acar R., Igret N., Yildiz B., ERTÜRK İ., et al.

Journal of Oncological Science , cilt.8, sa.1, ss.27-33, 2022 (Scopus, TRDizin)

93. Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

Gurbuz M., Dogan I., Akkus E., KARADAĞ İ., KARAKAYA S., Erol C., et al.

Journal of Oncological Science , cilt.8, sa.1, ss.14-19, 2022 (Scopus, TRDizin)

94. High-dose Chemotherapy Response in Adults with Relapsed/Refractory Small Round Cell Tumours

AYKAN M. B., ERTÜRK İ., Acar R., Yildiran G. S., Yildiz B., KARADURMUŞ N.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.1, ss.51-56, 2022 (SCI-Expanded, Scopus)

Creative Commons License

95. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., AYKAN M. B., Kahraman S., et al.

Current Medical Research and Opinion , cilt.38, sa.10, ss.1751-1758, 2022 (SCI-Expanded, Scopus)

96. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Gumus M., Cicin I., Cicin I., Oksuz E., Oksuz E., KARADURMUŞ N., et al.

Health Economics Review , cilt.11, sa.1, 2021 (SSCI, Scopus)

97. Thirty-day mortality rates after immunotherapy initiation

SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Uçar G., KARADURMUŞ N., et al.

Immunotherapy , cilt.13, sa.17, ss.1419-1426, 2021 (SCI-Expanded, Scopus)

98. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

GÜVEN D. C., Acar R., YEKEDÜZ E., Bilgetekin I., Baytemur N. K., Erol C., et al.

Current Problems in Cancer , cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)

99. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

YEKEDÜZ E., ERTÜRK İ., Tural D., KARADURMUŞ N., KARAKAYA S., Hlzal M., et al.

Future Oncology , cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded, Scopus)

100. Yttrium-90 (Y-90) resin microsphere therapy for patients with unresectable hepatocellular carcinoma. Identification of successful treatment response predictors and patient selection

ARSLAN N., İNCE S., OKUYUCU K., ŞAN H., ALAGÖZ E., KARADURMUŞ N., et al.

Annali Italiani di Chirurgia , cilt.92, sa.6, ss.623-631, 2021 (SCI-Expanded, Scopus)

101. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Karacin C., EREN T., Zeynelgil E., İMAMOĞLU G. İ., ALTINBAŞ M., KARADAĞ İ., et al.

Future Oncology , cilt.17, sa.33, ss.4447-4456, 2021 (SCI-Expanded, Scopus)

102. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

Gürbüz M., Akkuş E., Sakin A., Urvay S., Demiray A. G., Şahin S., et al.

Tumori , cilt.107, sa.5, ss.416-423, 2021 (SCI-Expanded, Scopus)

103. Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation

ERTÜRK İ., KARADURMUŞ N., Kızıloz H., ACAR R., YILDIZ B., AYKAN M. B., et al.

Journal of Oncology Pharmacy Practice , cilt.27, sa.7, ss.1657-1664, 2021 (SCI-Expanded, Scopus)

104. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study

Soran A., DOĞAN L., Isik A., Ozbas S., Trabulus D. C., Demirci U., et al.

Annals of Surgical Oncology , cilt.28, sa.9, ss.5048-5057, 2021 (SCI-Expanded, Scopus)

105. Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma

PAYDAŞ S., Lacin S., DOĞAN M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., et al.

Leukemia Research , cilt.107, 2021 (SCI-Expanded, Scopus)

106. “Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?

Karacin C., Acar R., BAL Ö., EREN T., ŞENDUR M. A. N., Acikgoz Y., et al.

Supportive Care in Cancer , cilt.29, sa.8, ss.4587-4593, 2021 (SCI-Expanded, Scopus)

107. Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; A new entity

KÜÇÜKARDA A., Sayln S., Gokyer A., AYKAN M. B., KARADURMUŞ N., Cicin I.

Immunotherapy , cilt.13, sa.7, ss.565-570, 2021 (SCI-Expanded, Scopus)

108. Clinical presentation and course of the novel coronavirus disease 2019 in patients with various types of cancer: A retrospective case-control analysis of an experienced cancer center in Turkey

Acar R., YILMAZ TEHLİ G., SAVAŞÇI Ü., AYKAN M. B., Kiziloz H., CÜCE F., et al.

Journal of Cancer Research and Therapeutics , cilt.17, sa.2, ss.556-564, 2021 (SCI-Expanded, Scopus)

109. IPS-3 Validation in 1012 cases with classical hodgkin lymphoma

PAYDAŞ S., Laçin S., DOĞAN M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., et al.

Leukemia Research , cilt.102, 2021 (SCI-Expanded, Scopus)

110. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer

Bilgetekin I., ERTÜRK İ., Basal F. B., Karacin C., KARADURMUŞ N., Oksuzoglu B., et al.

International Urology and Nephrology , cilt.53, sa.2, ss.301-307, 2021 (SCI-Expanded, Scopus)

111. Turkish society of medical oncology covid-19 pandemic advisory board updated recommendations for medical oncologists: Included vaccination

Sümbül A. T., YALÇIN S. S., ÖZET A., Ünal S., DİZDAR Ö., AKBULUT H., et al.

Journal of Oncological Science , cilt.7, sa.1, ss.1-6, 2021 (Scopus, TRDizin)

112. Effectiveness of bendamustine in relapsed or refractory lymphoma cases: A Turkish oncology group study

KARADURMUŞ N., PAYDAŞ S., Esin E., Surmeli Z. G., Yildiz B., ERTÜRK İ., et al.

Archives of Medical Science , cilt.17, sa.4, ss.920-927, 2021 (SCI-Expanded, Scopus)

Creative Commons License

113. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥ 75) patients

Alkan A., Güç Z. G., Gürbüz M., Özgün G., Değirmencioğlu S., DOĞAN M., et al.

Journal of Men's Health , cilt.17, sa.4, ss.128-134, 2021 (SCI-Expanded, SSCI, Scopus)

114. Retrospective analysis of patients with relapsed/refractory medulloblastoma after autologous stem cell transplantation

Acar R., ERTÜRK İ., Kizilöz H., Okçelik S., Yildiz B., AYKAN M. B., et al.

Gulhane Medical Journal , cilt.62, sa.4, ss.266-271, 2020 (Scopus, TRDizin)

115. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz H., Ozbalak M., KARADURMUŞ N., PAYDAŞ S., Turker A., TOPTAŞ T., et al.

Annals of Hematology , cilt.99, sa.11, ss.2565-2576, 2020 (SCI-Expanded, Scopus)

116. Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)

Türkkan G., Alkan A., PAYDAŞ S., Tanrıverdi Ö., Karakaş Y., KARADURMUŞ N., et al.

Indian Journal of Hematology and Blood Transfusion , cilt.36, sa.4, ss.640-645, 2020 (SCI-Expanded, Scopus)

117. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

Hizal M., Sendur M. A., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus)

118. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., KARAKAYA S., Bilgin B., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus)

119. Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology Group study

Yildiz B., KÜÇÜKARDA A., Gokyer A., Demiray A. G., PAYDAŞ S., Aral I. P., et al.

Journal of B.U.ON. , cilt.25, sa.2, ss.1130-1135, 2020 (SCI-Expanded, Scopus)

120. What is the optimal high-dose treatment following autologous stem cell transplantation in relapsed or refractory germ cell cancer: A retrospective comparison of high-dose ICE and highdose CE

Yildiz B., Aral I. P., Balyemez U., Esin E., ERTÜRK İ., Acar R., et al.

Journal of B.U.ON. , cilt.25, sa.2, ss.1136-1140, 2020 (SCI-Expanded, Scopus)

121. Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Oktay E., Levent M., Gelincik H., Aktaş G., Yumuk F., KORAL L., et al.

Journal of Cancer Education , cilt.35, sa.1, ss.69-75, 2020 (SCI-Expanded, Scopus)

122. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience

Özbalak M., SALİHOĞLU A., Soysal T., Karadoğan İ., PAYDAŞ S., Özdemir E., et al.

Annals of Hematology , cilt.99, sa.2, ss.301-307, 2020 (SCI-Expanded, Scopus)

123. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA

Disel U., Madison R., Abhishek K., Chung J. H., Trabucco S. E., Matos A. O., et al.

Oncologist , cilt.25, sa.1, 2020 (SCI-Expanded, Scopus)

124. Outcomes of bladder preservation therapy on survival in patients with muscle-invasive bladder cancer

Özaydın Ş., ATAŞ E., KARADURMUŞ N., Emirzeoğlu L., Arpacı F.

Archivos Espanoles de Urologia , cilt.73, sa.1, ss.41-46, 2020 (SCI-Expanded, Scopus)

125. Autologous stem cell transplantation in patients with extragonadal germ cell tumors: A single center experience

Yildiz B., Aral I. P., BAŞGÖZ B. B., ERTÜRK İ., Acar R., KARADURMUŞ N.

Gulhane Medical Journal , cilt.62, ss.97-102, 2020 (Scopus, TRDizin)

126. Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial

Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER Ö., Turhal N. S., et al.

Balkan Medical Journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin)

127. Gemcitabine, oxaliplatin and paclitaxel (Gempox) in patients with relapsed or refractory germ cell tumors after high dose chemotherapy, a retrospective single-center experience

Acar R., ERTÜRK İ., Kiziloz H., Okcelik S., Yildiz B., AYKAN M. B., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.30, sa.4, ss.191-196, 2020 (SCI-Expanded, Scopus, TRDizin)

128. Immunotherapy and multidisciplinary approach to treatment in lung cancer Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım

KARADURMUŞ N., KAYA A., Göksel T., Yilmaz Ü., Tülek N.

Tuberkuloz ve Toraks , cilt.68, sa.1, ss.66-75, 2020 (ESCI, Scopus, TRDizin)

Creative Commons License

129. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., BİLİCİ A., Cicin I., KÖSTEK O., Kaplan M., et al.

Cancer Chemotherapy and Pharmacology , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus)

130. Is there a role of high dose chemotherapy and autologous stem cell transplantation in the treatment of Ewing’s sarcoma and osteosarcomas?

KARADURMUŞ N., ŞAHİN U., BAŞGÖZ B. B., DEMİRER T.

Journal of B.U.ON. , cilt.23, sa.5, ss.1235-1241, 2018 (SCI-Expanded, Scopus)

131. Endpoints in oncology clinical trials

Kilickap S., Demirci U., KARADURMUŞ N., DOĞAN M., Akinci B., ŞENDUR M. A. N.

Journal of B.U.ON. , cilt.23, ss.1-6, 2018 (SCI-Expanded, Scopus)

132. Retrospective analysis of patients with relapsed or refractory germ cell tumors treated with autologous hematopoietic stem cell transplantation

ERTÜRK İ., Yildiz B., KARADURMUŞ N., TOSUN B., Esen R., Sürmeli Z. G., et al.

Gulhane Medical Journal , cilt.60, sa.4, ss.130-135, 2018 (Scopus, TRDizin)

133. A review of allogeneic hematopoietic stem cell transplantation in metastatic breast cancer

KARADURMUŞ N., ŞAHİN U., BAŞGÖZ B. B., Arpaci F., DEMİRER T.

International Journal of Hematology-Oncology and Stem Cell Research , cilt.12, sa.2, ss.111-116, 2018 (Scopus)

134. Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers

ERTÜRK İ., Yildiz B., KARADURMUŞ N., TOSUN B., Esen R., Acar R., et al.

Gulhane Medical Journal , cilt.60, sa.4, ss.145-150, 2018 (Scopus, TRDizin)

135. Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

YILDIZ İ., BİLİCİ A., KARADURMUŞ N., Ozer L., Tural D., Kaplan M. A., et al.

Tumori , cilt.104, sa.6, ss.444-450, 2018 (SCI-Expanded, Scopus)

136. Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience

İNCE S., Karaman B., ALAGÖZ E., KARADURMUŞ N., Şan H., ERÇİN C. N., et al.

Journal of gastrointestinal cancer , cilt.48, sa.3, ss.281, 2017 (Scopus)

137. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Bilir C., YILDIZ İ., BİLİCİ A., Ucar M., Berk V., Yıldız Y., et al.

Cancer Investigation , cilt.35, sa.4, ss.248-255, 2017 (SCI-Expanded, Scopus)

138. An overview of high dose chemotherapy with autologous stem cell rescue for germ cell tumors in current practice

Ozaydin S., ŞAHİN U., KARADURMUŞ N., Arpaci F., DEMİRER T.

Journal of B.U.ON. , cilt.22, sa.2, ss.306-311, 2017 (SCI-Expanded, Scopus)

139. Comparison of the clinical features and hematopoietic stem cell transplantation outcomes of mediastinal malignant germ cell tumors with nonmediastinal extragonadal placements

ÖCAL N., Yildiz B., KARADURMUŞ N., DOĞAN D., Ozaydin S., ÖÇAL R., et al.

OncoTargets and Therapy , cilt.9, ss.7445-7450, 2016 (SCI-Expanded, Scopus)

140. Complete remission on 18-fluorodeoxyglucose positron emission tomography/computed tomography after nivolumab treatment in a patient with indolent hodgkin lymphoma

ALAGÖZ E., İNCE S., OKUYUCU K., Ayan A., San H., KARADURMUŞ N.

Translational Cancer Research , cilt.5, sa.3, ss.320-323, 2016 (SCI-Expanded, Scopus)

141. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

SALİHOĞLU A., ELVERDİ T., Karadogan I., PAYDAŞ S., ÖZDEMİR E. R., Erdem G., et al.

Annals of Hematology , cilt.94, sa.3, ss.415-420, 2015 (SCI-Expanded, Scopus)

142. A very rare case - Hairy cell leukemia in patient with sarcoidosis

KARADURMUŞ N., Erdem G., Basaran Y., Naharci I., TAŞÇI C., Dogan T., et al.

Klinicka Onkologie , cilt.28, sa.3, ss.215-217, 2015 (Scopus)

143. Influences of treatment with amlodipine and valsartan on bone turnover markers and OPG/RANKL/RANK System in newly diagnosed hypertensive adults; Which is more beneficial?

Naharci M. I., Karaman M., Ahmet Ay S., Tapan S., Taşçi I., SAFER U., et al.

Turkish Nephrology, Dialysis and Transplantation Journal , cilt.23, sa.1, ss.40-45, 2014 (Scopus, TRDizin)

144. A rare presentation of follicular lymphoma: Cerebellar involvement, successfully treated with a combination of radiotherapy and chemotherapy

KARADURMUŞ N., Ataergin S., Erdem G., Cakar M., Emer O., Ozaydin S., et al.

Cancer Research and Treatment , cilt.45, sa.3, ss.234-238, 2013 (SCI-Expanded, Scopus)

145. A case with POEMS syndrome presenting with loss of vision and skeletal muscle strength Görme ve kas gücü kaybı ile gelen bir poems sendromu olgusu

Çakar M., KARADURMUŞ N., Altun B., Taşçi I., Erdem G., Naharci I., et al.

Turk Noroloji Dergisi , cilt.19, sa.1, ss.31-33, 2013 (Scopus)

146. MTHFR gene mutation in an elderly patient that comes with portal vein thrombosis and ascites: A case report Ileri yaşta portal ven trombozu ve assit ile gelen bir MTHFR gen mutasyonu olgusu

Çakar M., Demirbaş Ş., Kurt Ö., KARADURMUŞ N.

Gulhane Medical Journal , cilt.55, sa.1, ss.66-69, 2013 (Scopus, TRDizin)

147. A case of adult still's disease Erİşkİn stİll hastaliǧi tanisi konulan bİr olgu

TAŞÇI C., Balkan A., KARADURMUŞ N., YILMAZ S., ERDEM H., Naharci I., et al.

Anatolian Journal of Clinical Investigation , cilt.6, sa.4, ss.281-284, 2012 (Scopus)

148. The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis

TAŞÇI C., Ozkaya S., Ozkara B., Tozkoparan E., Ozkan M., KARADURMUŞ N., et al.

OncoTargets and Therapy , cilt.5, ss.385-390, 2012 (SCI-Expanded, Scopus)

149. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension

KARADURMUŞ N., Tapan S., Cakar M., Naharci I., Celik T., Tasci I., et al.

Clinical and Investigative Medicine , cilt.35, sa.1, 2012 (SCI-Expanded, Scopus)

150. Vitamin B 12 and folic acid levels as therapeutic target in preserving bone mineral density (BMD) of older men

Naharci I., Bozoglu E., KARADURMUŞ N., Emer O., Kocak N., Kilic S., et al.

Archives of Gerontology and Geriatrics , cilt.54, sa.3, ss.469-472, 2012 (SCI-Expanded, Scopus)

151. Rivastigmine associated hyponatremia in an older patient with alzheimer's disease

Naharci I. M., Bozoglu E., KARADURMUŞ N., Karaman M., Kurt O., Doruk H.

Journal of the American Geriatrics Society , cilt.59, sa.7, ss.1351-1352, 2011 (SCI-Expanded, SSCI, Scopus)

152. Oxidative stress status and plasma trace elements in patients with asthma or allergic rhinitis

Sagdic A., ŞENER O., Bulucu F., KARADURMUŞ N., ÖZEL H. E., YAMANEL H. L., et al.

Allergologia et Immunopathologia , cilt.39, sa.4, ss.200-205, 2011 (SCI-Expanded, Scopus)

153. Oxidative stress status in patients with chronic idiopathic urticaria

Sagdic A., ŞENER O., Bulucu F., KARADURMUŞ N., YAMANEL H. L., TAŞÇI C., et al.

Allergologia et Immunopathologia , cilt.39, sa.3, ss.150-153, 2011 (SCI-Expanded, Scopus)

154. A case report: Primary amiloidosis associated with immunoglobulin A type multiple myeloma

KARADURMUŞ N., ERTÜRK İ., Çakar M., Altun B., SAĞLAM K., Arpaci F.

Respiratory Medicine CME , cilt.4, sa.3, ss.131-132, 2011 (Scopus)

155. Decreased small dense LDL levels in Gilbert's syndrome

Tapan S., KARADURMUŞ N., Dogru T., ERÇİN C. N., Tasci I., Bilgi C., et al.

Clinical Biochemistry , cilt.44, sa.4, ss.300-303, 2011 (SCI-Expanded, Scopus)

156. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine

Naharci M. I., KARADURMUŞ N., Demir O., Bozoglu E., Ak M., Doruk H.

American Journal of Psychiatry , cilt.168, sa.2, ss.212-213, 2011 (SCI-Expanded, SSCI, Scopus)

157. Bronchiolitis obliterans with organizing pneumonia associated with Aspergillus fumigatus

TAŞÇI C., Ozkan M., KARADURMUŞ N., Naharci I., Cakar M., Safali M., et al.

Respiratory Medicine CME , cilt.4, sa.2, ss.64-66, 2011 (Scopus)

158. Analysis of insulin sensitivity according to vitamin D levels in prediabetic elderly subjects Prediyabetli yaşlilarda vitamin D düzeylerine göre insülin duyarliliǧinin incelenmesi

Naharci M. I., Bozoǧlu E., KARADURMUŞ N., Türker T., SERDAR M. A., Doruk H.

Gulhane Medical Journal , cilt.53, sa.4, ss.271-276, 2011 (Scopus, TRDizin)

159. Acute Lymphoblastic Leukemia presenting with oculomotor nerve palsy

Öz O., Akgün H., Battal B., Yücel M., Öztürk K., KARADURMUŞ N., et al.

Acta Neurologica Belgica , cilt.111, sa.4, ss.362-364, 2011 (SCI-Expanded, Scopus)

160. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease

Kilciler G., Genc H., Tapan S., Ors F., Kara M., KARADURMUŞ N., et al.

Upsala Journal of Medical Sciences , cilt.115, sa.4, ss.253-259, 2010 (SCI-Expanded, Scopus)

161. Do adiponectin isoforms in older adults with or without coronary artery disease differ according to glucose tolerance states and lifestyle factors?

Naharci M. I., KARADURMUŞ N., Bozoglu E., Doruk H.

Journal of the American Geriatrics Society , cilt.58, sa.11, ss.2235-2236, 2010 (SCI-Expanded, SSCI, Scopus)

162. An elderly diabetic case of ochronosis with depression and chronic pain

Naharci M. I., Ak M., Bozoglu E., KARADURMUŞ N., IŞIK A. T., Doruk H.

Endokrynologia Polska , cilt.61, sa.6, ss.710-713, 2010 (Scopus)

163. Transforming growth factor β (TGF-β) levels in otherwise healthy subjects with impaired glucose tolerance

Genc H., KARADURMUŞ N., Kisa U., Tapan S., Naharci I., Sonmez A., et al.

Endokrynologia Polska , cilt.61, sa.6, ss.691-694, 2010 (Scopus)

164. The effect of increased cortisol levels on serum glucagonlike peptide-1 in patients with type 2 diabetes mellitus Tip 2 diabetes mellitus hastalarindaki artmiş serum kortizol düzeyinin serum glukagon-like peptid 1 üzerine etkileri

KARADURMUŞ N., Çakar M., Naharci M. I., Üçkaya G., ŞAHİN M., Kenan S., et al.

Anatolian Journal of Clinical Investigation , cilt.4, sa.2, ss.80-89, 2010 (Scopus)

165. The relationship of plasma adiponectin with liver fibrosis in morbid obesity

Dogru T., KARADURMUŞ N., Kilciler G., Tapan S., ERÇİN C. N.

Obesity Surgery , cilt.20, sa.10, ss.1462, 2010 (SCI-Expanded, Scopus)

166. Microalbuminuria and nonalcoholic fatty liver disease

Dogru T., Genc H., Kara M., KARADURMUŞ N.

Metabolism: Clinical and Experimental , cilt.59, sa.9, 2010 (SCI-Expanded, Scopus)

167. The relationship between ghrelin levels and insulin resistance in men with idiopathic hypogonadotrophic hypogonadism at diagnosis and after therapy

Naharci M. I., Bolu E., KARADURMUŞ N., Basaran Y.

Endokrynologia Polska , cilt.61, sa.4, ss.351-358, 2010 (Scopus)

168. Plasma apelin levels in subjects with nonalcoholic fatty liver disease

ERÇİN C. N., Dogru T., Tapan S., Kara M., HAYMANA C., KARADURMUŞ N., et al.

Metabolism: Clinical and Experimental , cilt.59, sa.7, ss.977-981, 2010 (SCI-Expanded, Scopus)

169. Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide

KARADURMUŞ N., Naharci M. I.

Clinical Biochemistry , cilt.43, sa.9, ss.774, 2010 (SCI-Expanded, Scopus)

170. Potential benefits of hyperbaric oxygen therapy on atherosclerosis and glycaemic control in patients with diabetic foot

KARADURMUŞ N., ŞAHİN M., TAŞÇI C., Naharci I., Ozturk C., Ilbasmis S., et al.

Endokrynologia Polska , cilt.61, sa.3, ss.275-279, 2010 (Scopus)

171. Retrospectively evalution of the 321 young age cases with the diagnosis of community based pneumonia Toplum kökenli̇ pnömoni̇ tanisi konulan genç yaştaki̇ 321 olgunun retrospekti̇f olarak deǧerlendi̇ri̇lmesi̇

TAŞÇI C., KARADURMUŞ N., Maden E., Deniz Ö., Özkan M., Bilgiç H.

Anatolian Journal of Clinical Investigation , cilt.4, sa.1, ss.28-31, 2010 (Scopus)

172. Comparison of lymphomononuclear cell energy metabolism between healthy, impaired glucose intolerance and type 2 diabetes mellitus patients

ÖZSARI L., KARADURMUŞ N., ŞAHİN M., Uckaya G., Ural A., Kutlu M.

Endocrine , cilt.37, sa.1, ss.135-139, 2010 (SCI-Expanded, Scopus)

173. Comment and reply on: Serum chemerin and vaspin in non-alcoholic fatty liver disease

Dogru T., KARADURMUŞ N., Tapan S., Genc H.

Scandinavian Journal of Gastroenterology , cilt.45, sa.7-8, ss.1000-1002, 2010 (SCI-Expanded, Scopus)

174. Analysis of risk factors in older men with osteoporosis Yaşlı erkeklerde osteoporoz risk faktörlerinin deǧerlendirilmesi

Naharci M. I., Doruk H., Bozoǧlu E., Onar T., IŞIK A. T., KARADURMUŞ N., et al.

Gulhane Medical Journal , cilt.52, sa.3, ss.167-171, 2010 (Scopus, TRDizin)

175. Lower leptin levels in young non-obese male smokers than non-smokers

Koc B., Bulucu F., KARADURMUŞ N., ŞAHİN M.

Upsala Journal of Medical Sciences , cilt.114, sa.3, ss.165-169, 2009 (SCI-Expanded, Scopus)

176. Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity

Bulucu F., ÖÇAL R., KARADURMUŞ N., ŞAHİN M., KENAR L., Aydin A., et al.

Biological Trace Element Research , cilt.132, sa.1-3, ss.184-196, 2009 (SCI-Expanded, Scopus)

177. Melkersson-Rosenthal syndrome and Hashimoto's thyroiditis: A case report

KARADURMUŞ N., ŞAHİN M., KAHRAMAN M. E., YILMAZ S., TAŞÇI C., Inal S., et al.

Turkish Journal of Endocrinology and Metabolism , cilt.13, sa.2, ss.40-42, 2009 (Scopus)

178. Respiratory function parameters of Turkish jet pilots

Özkan M., TAŞÇI C., KARADURMUŞ N., Satilmiş I., Balkan A., Tozkoparan E., et al.

Turkiye Klinikleri Journal of Medical Sciences , cilt.29, sa.5, ss.1168-1171, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

179. Efficacy of hyperbaric oxygen therapy in post-dural puncture headache Dura ponksiyonundan sonra gelişen baş aǧrisinda hiperbarik oksijen tedavisinin etkinliǧi

Şenol M. G., Kendirli M. T., Şen A., KARADURMUŞ N., Kendirli N., Şen H., et al.

Turkiye Klinikleri Journal of Medical Sciences , cilt.29, sa.6, ss.1618-1622, 2009 (SCI-Expanded, Scopus)

180. Adipose tissue 11-beta-Hydroxysteroid Dehydrogenase Type 1 and Hexose-6-Phosphate Dehydrogenase gene expressions are increased in patients with type 2 diabetes mellitus

Üçkaya G., KARADURMUŞ N., Kutlu O., Çorakçi A., KIZILDAĞ S., Ural A. U., et al.

Diabetes Research and Clinical Practice , cilt.82, sa.SUPPL. 2, 2008 (SCI-Expanded, Scopus)

181. An atypical initial presentation of Crohn's disease.

KARADURMUŞ N., Ertuǧrul I., Sõnmez A., Ustün I., Inal S., Ozakyol A.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.19, sa.4, ss.292-293, 2008 (Scopus, TRDizin)

182. The effect of short-term hypobaric hypoxic exposure on intraocular pressure

Karadag R., Sen A., Golemez H., Basmak H., Yildirim N., KARADURMUŞ N., et al.

Current Eye Research , cilt.33, sa.10, ss.864-867, 2008 (SCI-Expanded, Scopus)

183. Isolated left pulmonary artery agenesis

TAŞÇI C., Öztürk C., KARADURMUŞ N., Ertuǧrul I., Bal Ş., Balkan A., et al.

Anadolu Kardiyoloji Dergisi , cilt.8, sa.4, ss.308-310, 2008 (Scopus, TRDizin)

184. The association of D-dimer levels with other prognostic factors in patients with lung cancer

Inal S., TAŞÇI C., KARADURMUŞ N., Kuzhan O., Balkan A., Özkan M., et al.

Turkish Journal of Medical Sciences , cilt.38, sa.3, ss.209-217, 2008 (Scopus, TRDizin)

185. The importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbations

TAŞÇI C., Balkan A., KARADURMUŞ N., Inal S., Kiliç S., Özkan M., et al.

Turkish Journal of Medical Sciences , cilt.38, sa.2, ss.139-144, 2008 (Scopus, TRDizin)

186. Combined heterozygote factor V Leiden mutation and anticardiolipin antibody positivity in a young patient with spontaneous deep vein thrombosis

KARADURMUŞ N., Öztürk C., Sönmez A., Doǧru T., Inal S., TAŞÇI C., et al.

Anadolu Kardiyoloji Dergisi , cilt.8, sa.1, ss.71-73, 2008 (Scopus, TRDizin)

187. Detrimental effects of N-acetylcysteine plus desferoxamine combination in an experimental nephrotic syndrome model

Bulucu F., Oktenli C., KENAR L., Koc B., ÖÇAL R., KARADURMUŞ N., et al.

International Journal of Toxicology , cilt.26, sa.6, ss.525-532, 2007 (SCI-Expanded, Scopus)

188. The rate of pyrin mutations in critically ill patients with systemic inflammatory response syndrome and sepsis: A pilot study

Koc B., Oktenli C., Bulucu F., KARADURMUŞ N., Sanisoglu S. Y., Gul D.

Journal of Rheumatology , cilt.34, sa.10, ss.2070-2074, 2007 (SCI-Expanded, Scopus)

Metrikler

Yayın

188

Yayın (WoS)

162

Yayın (Scopus)

188

H-İndeks (WoS)

23

Atıf (Scopus)

1706

H-İndeks (Scopus)

23

Atıf (TrDizin)

6

H-İndeks (TrDizin)

2

Atıf (Diğer Toplam)

6

Proje

1

Açık Erişim

13

BM Sürdürülebilir Kalkınma Amaçları

SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER